Table 1.
Demographic, clinical, and DAT binding data in the 2 groups at baseline and follow‐up
| Baseline | PDP−, n = 355 | PDP+, n = 30 | Sig. (2‐tailed) |
|---|---|---|---|
| Age, years (SD) | 61.35 (9.9) | 64.07 (8.7) | 0.15 |
| UPDRS part III score (SD) | 20.05 (8.9) | 22.83 (9.6) | 0.10 |
| MoCA score (SD) | 27.12 (2.3) | 26.70 (2.9) | 0.34 |
| Sex, male, % | 65.9 | 70 | 0.65 |
| Mean striatal DAT binding | 1.42 (0.4) | 1.15 (0.4) | <0.001 |
| Follow‐up | |||
| LEDD,* mg (SD) | 631.34 (629.6) | 526.92 (379.1) | 0.37 |
| Prospective levodopa use, % | 84.8 | 96.7 | 0.07 |
| Prospective dopamine agonist use, % | 60.8 | 53.3 | 0.42 |
t tests for continuous data and chi‐square tests for categorical data.
*
LEDD at time of PDP onset for PDP+ and last follow‐up visit for PDP−.
DAT, dopamine transporter; PDP, Parkinson's disease psychosis; SD, standard deviation; UPDRS, Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive Assessment; LEDD, levodopa equivalent daily dose.